Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

Valneva, a Saint-Herblain, France-headquartered vaccine company, has entered into an agreement with the UK government to provide up to 190 million doses of its COVID-19 vaccine candidate, VLA2001, over a five-year period, in a deal worth up to $1.6...

Novavax, a Gaithersburg, Maryland-based clinical-stage vaccine company, has amended a previous agreement with the Serum Institute of India (SII), a Pune, Maharashtra, India-based vaccine manufacturer, under which SII will produce the antigen...

Takeda has opened a new 24,000-square-foot R&D and clinical cell-therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts. The facility will produce cell therapies for clinical evaluation from discovery through Phase...

Merck & Co. and Seattle Genetics, a Bothell, Washington-headquartered biopharmaceutical company, have formed a collaboration, in a deal worth up to $4.2-billion, for Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody drug...

Gilead Sciences has agreed to acquire Immunomedics, a Morris Plains, New Jersey-based clinical-stage biopharmaceutical company focused on antibody-drug conjugates (ADCs), for $21 billion. Immunomedics’ lead product is Trodelvy (sacituzumab...

The US Department of Health and Human Services (HHS) and the US Department of Defense (DoD) released two documents outlining the US government’s strategy to deliver COVID-19 vaccine doses once vaccines are proven effective and safe and are...

A roundup of news from Germany (Bayer, Recursion), India (Mylan), Spain (Grifols, Alkahest), and the US (Merck KGaA, Pfizer, NKMax America). Germany Bayer, Recursion in AI Drug-Discovery Pact; Bayer Takes $50-M StakeBayer and Recursion...